The formulation and delivery of biopharmaceutical drugs, such as monoclonal antibodies
and recombinant proteins, poses substantial challenges owing to their large size and …

Protein aggregation has been recognized as one of the major challenges in the
development and commercialization of successful protein-based drug products because of …

Despite the therapeutic success of monoclonal antibodies (mAbs), early identification of
developable mAb drug candidates with optimal manufacturability, stability, and delivery …

The dynamics of proteins in solution includes a variety of processes, such as backbone and
side-chain fluctuations, interdomain motions, as well as global rotational and translational …

High-concentration protein formulation (HCPF) is a term that is used to describe protein
formulations, mostly monoclonal antibody (mAb) drugs, at high protein concentration. The …

Protein pharmaceuticals have become a significant class of marketed drug products and are
expected to grow steadily over the next decade. Development of a commercial protein …

Looking at globular proteins with the eyes of a colloid scientist has a long tradition, in fact a
significant part of the early colloid literature was focused on protein solutions. However, it …

It is well recognized that protein product development is far more challenging than that for
small‐molecule drugs. The major challenges include inherent sensitivity to different types of …

Colloidal liquids interacting with short range attraction and long range repulsion, such as
proposed for some protein solutions, have been found to exhibit novel states consisting of …

In this review, we discuss recent advances in the investigation of colloidal systems
interacting via a combination of short-range attraction and long-range repulsion. The …